These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 39340205)
21. A real-world pharmacovigilance study of FDA adverse event reporting system events for Lutetium-177-PSMA-617. Wu S; Hu W; Chen M; Xiao X; Liu R Sci Rep; 2024 Oct; 14(1):25712. PubMed ID: 39468291 [TBL] [Abstract][Full Text] [Related]
22. Adverse events with pemigatinib in the real world: a pharmacovigilance study based on the FDA Adverse Event Reporting System. Zhao D; Long X; Wang J Expert Opin Drug Saf; 2024 May; 23(5):599-605. PubMed ID: 38553867 [TBL] [Abstract][Full Text] [Related]
23. Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System. Zhao D; Long X; Zhou J; Wang J Drugs R D; 2023 Dec; 23(4):403-409. PubMed ID: 37700091 [TBL] [Abstract][Full Text] [Related]
24. A real-world disproportionality analysis of ospemifene: data mining of the public version of FDA adverse event reporting system. Wen H; Lu C; Zhang M; Qi X Expert Opin Drug Saf; 2023; 22(11):1133-1142. PubMed ID: 37578751 [TBL] [Abstract][Full Text] [Related]
25. Safety assessment of KRAS (G12C) inhibitors based on the FDA Adverse Event Reporting System (FAERS) database: A real-world pharmacovigilance study. Chen M; Huang Y; Jiang S; Ke C Lung Cancer; 2024 Oct; 196():107966. PubMed ID: 39342769 [TBL] [Abstract][Full Text] [Related]
26. A real-world pharmacovigilance study of FDA adverse event reporting system events for sildenafil. Wang Y; Zhao B; Yang H; Wan Z Andrology; 2024 May; 12(4):785-792. PubMed ID: 37724699 [TBL] [Abstract][Full Text] [Related]
27. Post-Marketing Safety Concerns with Upadacitinib: A Disproportionality Analysis of the FDA Adverse Event Reporting system. Wu XP; Lu XK; Wang ZT; Huang L; Cai RW; Yu HM; Li JY; Xiao J Expert Opin Drug Saf; 2023; 22(10):975-984. PubMed ID: 37310063 [TBL] [Abstract][Full Text] [Related]
28. Safety of daratumumab in the real-world: a pharmacovigilance study based on FAERS database. Wu J; Wu H; Chen L; Liang H; Huang G; Yang S; Chen B; Noguchi Y; Shen Y Expert Opin Drug Saf; 2024 Jul; 23(7):905-916. PubMed ID: 38108285 [TBL] [Abstract][Full Text] [Related]
29. Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System. Liu Y; Dong C; He X; Shu Y; Wu P; Zou J J Pharm Pharm Sci; 2022; 25():377-390. PubMed ID: 36608646 [TBL] [Abstract][Full Text] [Related]
30. Analysis of the nervous system and gastrointestinal adverse events associated with solifenacin in older adults using the US FDA adverse event reporting system. Nicholls C; Chyou TY; Nishtala PS Int J Risk Saf Med; 2023; 34(1):63-73. PubMed ID: 35491805 [TBL] [Abstract][Full Text] [Related]
31. Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database. Yang Q; Wang J; Wang M; Zhang S; He QQ BMC Pharmacol Toxicol; 2024 Sep; 25(1):64. PubMed ID: 39267168 [TBL] [Abstract][Full Text] [Related]
32. Adverse events analysis of Relugolix (Orgovyx®) for prostate cancer based on the FDA Adverse Event Reporting System (FAERS). Li R; Chen X; Wang Y PLoS One; 2024; 19(10):e0312481. PubMed ID: 39436909 [TBL] [Abstract][Full Text] [Related]
33. Safety evaluation of bempedoic acid: A pharmacovigilance analysis using FDA adverse event reporting system data. Li B; Zhang J; Huang A; Chen Y; Wei Q Int J Cardiol; 2024 Oct; 412():132305. PubMed ID: 38944350 [TBL] [Abstract][Full Text] [Related]
34. Discovering clinical drug-drug interactions with known pharmacokinetics mechanisms using spontaneous reporting systems and electronic health records. Jeong E; Su Y; Li L; Chen Y J Biomed Inform; 2024 May; 153():104639. PubMed ID: 38583580 [TBL] [Abstract][Full Text] [Related]
35. Pregnancy-related adverse events associated with statins: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS). Wu T; Shi Y; Zhu B; Li D; Li Z; Zhao Z; Zhang Y Expert Opin Drug Saf; 2024 Mar; 23(3):313-321. PubMed ID: 37612600 [TBL] [Abstract][Full Text] [Related]
36. Does eltrombopag lead to thrombotic events? A pharmacovigilance study of the FDA adverse event reporting system. Jiang JJ; Zhao B; Li J J Clin Pharm Ther; 2022 Oct; 47(10):1556-1562. PubMed ID: 35644838 [TBL] [Abstract][Full Text] [Related]
37. A real-world pharmacovigilance analysis of eslicarbazepine acetate using the FDA adverse events reporting system (FAERS) database from 2013 (Q4) to 2024 (Q1). Tang H; Xu J; Zhang X; Chen C; Song G; Ma R; Zhao J; Zhao Q Front Pharmacol; 2024; 15():1463560. PubMed ID: 39372199 [TBL] [Abstract][Full Text] [Related]
38. Assessing taxane-associated adverse events using the FDA adverse event reporting system database. Lao DH; Chen Y; Fan J; Zhang JZ Chin Med J (Engl); 2021 Jun; 134(12):1471-1476. PubMed ID: 34074841 [TBL] [Abstract][Full Text] [Related]
39. Disproportionality Analysis of Nusinersen in the Food and Drug Administration Adverse Event Reporting System: A Real-World Postmarketing Pharmacovigilance Assessment. Li Y; Zhang N; Jiang T; Gan L; Su H; Wu Y; Yang X; Xiang G; Ni R; Xu J; Li C; Liu Y Pediatr Neurol; 2024 Sep; 158():71-78. PubMed ID: 38981277 [TBL] [Abstract][Full Text] [Related]
40. A disproportionality analysis of low molecular weight heparin in the overall population and in pregnancy women using the FDA adverse event reporting system (FAERS) database. Xu H; Xu N; Wang Y; Zou H; Wu S Front Pharmacol; 2024; 15():1442002. PubMed ID: 39188956 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]